Enliven Therapeutics (ELVN) Payables (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Payables data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 4.99% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 4.99% YoY), and the FY2025 full-year result was $2.2 million, up 60.88% from the prior year.
• Payables declined to $1.6 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $5.9 million in Q1 2023 to a low of $532000.0 in Q4 2023.
• A 5-year average of $2.0 million and a median of $1.6 million in 2025 frame the typical range for Payables.
• Peak annual rise in Payables reached 211.04% in 2023, while the deepest fall reached 84.53% in 2023.
• Tracing ELVN's Payables over 5 years: stood at $3.4 million in 2022, then slumped by 84.53% to $532000.0 in 2023, then soared by 152.26% to $1.3 million in 2024, then soared by 60.88% to $2.2 million in 2025, then retreated by 24.04% to $1.6 million in 2026.
• Business Quant data shows ELVN's Payables at $1.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.4 million in Q3 2025.